poisar

Stocks · News reference

Jazz Pharmaceuticals' Two Ziihera-Containing Regimens Receives FDA Approval To Treat Adults With Unresectable Locally Advanced Or Metastatic Her2-Positive Gastroesophageal Adenocarcinoma

Benzinga News-desk

Jazz Pharmaceuticals plc (NASDAQ:JAZZ) today announced that the U.S. Food and Drug Administration (FDA) approved two Ziihera® (zanidatamab-hrii)-containing regimens for the first-line treatment of adults with

More stocks newsConnected markets

Reference Details

Connected Markets

Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.

JAZZONCZYME
Source
benzinga
Observed
Checked
Cadence
Captured once, then retained as an archive reference
Status
fresh

Keep reading

  1. SEC EDGAR

    8-K filing — Jazz Pharmaceuticals plc (JAZZ)

    Filed: 2026-08-31 AccNo: 0001193125-26-377073 Size: 1 MB Item 1.01: Entry into a Material Definitive Agreement Item 2.03: Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant Item 3.02: Unregistered Sales of Equity Securities Item 8.01: Other Events Item 9.01: Financial Statements and Exhibits

    JAZZ